Your browser doesn't support javascript.
loading
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Makielski, Rory J; Lubner, Sam J; Mulkerin, Daniel L; Traynor, Anne M; Groteluschen, David; Eickhoff, Jens; LoConte, Noelle K.
Affiliation
  • Makielski RJ; Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, rmakielski@uwhealth.org.
Cancer Chemother Pharmacol ; 76(2): 317-23, 2015 Aug.
Article in En | MEDLINE | ID: mdl-26068189
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2015 Document type: Article Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pancreatic Neoplasms / Adenocarcinoma / Antineoplastic Combined Chemotherapy Protocols Type of study: Clinical_trials Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2015 Document type: Article Country of publication: